Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation

Transfusion

Volumn 42, Issue 11, 2002, Pages 1458-1465

  Molinaro, Giuseppe ^a,b   Adam, Albert ^a,b   Lepage, Yves ^a,b   Hammerschmidt, Dale ^a,b   Koenigbauer, Ulrike ^a,b   Eastlund, Ted ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ANTINEOPLASTIC AGENT; BRADYKININ; BRADYKININ, DES ARG(9); BRADYKININ, DES-ARG(9)-; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DRUG DERIVATIVE; GLASS; LISINOPRIL; METALLOPROTEINASE; MICROSPHERE; MITOMYCIN; STAPHYLOCOCCUS PROTEIN A;

ACUTE DISEASE; ARTICLE; ASTHMA; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTRICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUSHING; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; LEIOMYOSARCOMA; LUNG TUMOR; METASTASIS; MIDDLE AGED; UTERUS CANCER; VASODILATATION;

ACUTE DISEASE; AMINOPEPTIDASES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHMA; BRADYKININ; DOXORUBICIN; ELECTROSTATICS; FEMALE; FLUSHING; GLASS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; HYPERTENSION; HYPOTENSION; IMMUNOSORBENT TECHNIQUES; LEIOMYOSARCOMA; LISINOPRIL; LUNG NEOPLASMS; METALLOENDOPEPTIDASES; MICROSPHERES; MIDDLE AGED; MITOMYCIN; STAPHYLOCOCCAL PROTEIN A; UTERINE NEOPLASMS; VASODILATION;

EID: 0036832140     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2002.00196.x     Document Type: Article

References (56)

1. 1 Unger T, Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res 1994 ; 28: 146 ‐ 58.
2. 2 Verresen L, Waer M, Vanrenterghem Y, Michielsen P. Angiotensin‐converting‐enzyme inhibitors and anaphylactoid reactions to high‐flux membrane dialysis. Lancet 1990 ; 336: 1360 ‐ 2.
3. 3 Hume HA, Popovsky MA, Benson K, et al. Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion 1996 ; 36: 904 ‐ 9.
4. 4 Fried MR, Eastlund T, Christie B, et al. Hypotensive reactions to white cell reduced plasma in a patient undergoing angiotensin‐converting enzyme inhibitor therapy. Transfusion 1996 ; 36: 900 ‐ 3.
5. 5 Mair B, Leparc GF. Hypotensive reactions associated with platelet transfusions and angiotensin‐converting enzyme inhibitors. Vox Sang 1998 ; 74: 27 ‐ 30.
6. 6 Sweeney JD, Dupuis M, Mega AP. Hypotensive reactions to red cells filtered at the bedside, but not to those filtered before storage, in patients taking ACE inhibitors (letter). Transfusion 1998 ; 38: 410 ‐ 1 ; discussion 413‐5.
7. 7 Quillen K. Hypotensive transfusion reactions in patients taking angiotensin‐converting‐enzyme inhibitors. N Engl J Med 2000 ; 343: 1422 ‐ 3.
8. 8 Yenicesu I, Tezcan I, Tuncer AM. Hypotensive reactions during platelet transfusions (letter). Transfusion 1998 ; 38: 410 ; discussion 413 ‐5.
9. 9 Petrucco A, Bordin P, Da Col PG, et al. Hypotension during sham apheresis in a patient taking ACE inhibitors (letter). JAMA 1995 ; 273: 520 ‐ 1.
10. 10 Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors (letter). Lancet 1992 ; 340: 908 ‐ 9.
11. 11 Kroon AA, Mol MJ, Stalenhoef AH. Ace inhibitors and LDL‐apheresis with dextran sulphate adsorption (letter). Lancet 1992 ; 340: 1476.
12. 12 Agishi T. Anion‐blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate‐cellulose column while receiving ACE inhibitors (letter). JAMA 1994 ; 271: 195 ‐ 6.
13. 13 Siami GA, Siami FS, Morrow JD, Stone WJ. Cryofiltration apheresis and plasma fractionation causing anaphylactoid reactions in patients receiving angiotensin converting enzyme inhibitors. Ther Apher 1997 ; 1: 325 ‐ 9.
14. 14 Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin‐converting enzyme inhibitors and apheresis. Transfusion 1994 ; 34: 891 ‐ 4.
15. 15 Brecher ME, Owen HG, Collins ML. Apheresis and ACE inhibitors (letter). Transfusion 1993 ; 33: 963 ‐ 4.
16. 16 Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood 1997 ; 90: 3819 ‐ 43.
17. 17 Blais C Jr, Marc‐Aurele J, Simmons WH, et al. Des‐Arg 9 ‐bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999 ; 20: 421 ‐ 30.
18. 18 Verresen L, Fink E, Lemke D, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994 ; 45: 1497 ‐ 503
19. 19 Cyr M, Eastlund T, Blais C Jr, et al. Bradykinin metabolism and hypotensive transfusion reactions. Transfusion 2001 ; 41: 136 ‐ 50.
20. 20 Cyr M, Hume HA, Champagne M, et al. Anomaly of the des‐Arg 9 ‐bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion 1999 ; 39: 1084 ‐ 8.
21. 21 Hild M, Soderstrom T, Egberg N, Lundahl J. Kinetics of bradykinin levels during and after leukocyte filtration of platelet concentrates. Vox Sang 1998 ; 75: 18 ‐ 25.
22. 22 Davenport RD, Penezina OP. Cleavage of high molecular weight kininogen induced by filtration of platelet concentrates (abstract). Transfusion 1997 ; 37: 104.
23. 23 Abe H, Ikebuchi K, Shimbo M, Sekiguchi S. Hypotensive reactions with a white cell reduction filter: activation of kallikrein‐kinin cascade in a patient (letter). Transfusion 1998 ; 38: 411 ‐ 2.
24. 24 Takahashi TA, Hosoda M, Abe H, Sekiguchi S. Bradykinin formation in a platelet concentrate filtered with a leukocyte‐removal filter made of nonwoven polyester filters with a negatively charged surface (abstract). Transfusion 1994 ; 34 (Suppl): 22.
25. 25 Takahashi TA, Hosoda M, Abe H, et al. Bradykinin generation in red cell concentrates filtered with leukocyte‐removal filters (abstract). Transfusion 1995 ; 35 (Suppl): S76.
26. 26 Shiba M, Tadokoro K, Sawanobori M, et al. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell‐removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. Transfusion 1997 ; 37: 457 ‐ 62.
27. 27 Kojima S, Harada‐Shiba M, Nomura S, et al. Effect of nafomestat mesilate on bradykinin generation during low‐density lipoprotein apheresis using a dextran sulfate cellulose column. Trans Am Soc Artif Intern Organs 1991 ; 37: 644 ‐ 8.
28. 28 Koga N, Nagano T, Sato T, Kagasawa K. Anaphylactoid reaction and bradykinin generation in patients treated with LDL apheresis and ACE inhibitor. ASAIO J 1993 ; 39: M288 ‐ 91.
29. 29 Kojima S, Ogi M, Yoshitomi Y, et al. Changes in bradykinin and prostaglandin plasma levels during dextran‐ sulfate low‐density‐lipoprotein apheresis. Int J Artif Organs 1997 ; 20: 178 ‐ 83.
30. 30 Tsuboi Y, Takahashi M, Ishikawa M, et al. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Therapeutic Apheresis 1998 ; 2: 297 ‐ 9.
31. 31 Scott CF, Brandwein H, Whitbread J, Colman RW. Lack of clinically significant contact system activation during platelet concentrate filtration by leukocyte reduction filters. Blood 1998 ; 92: 616 ‐ 22.
32. 32 Colman RW, Scott CF. Hypotension reactions during transfusion: is bradykinin the culprit? (letter). Transfusion 1999 ; 39: 107 ‐ 9.
33. 33 Colman RW, Scott CF, Brandwein H, Whitbread J. More on kinogen measurements in platelet concentrates that are white cell (WBC) reduced with WBC‐reduction filters (letter). Transfusion 1996 ; 36: 939 ‐ 40.
34. 34 Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992 ; 44: 1 ‐ 80.
35. 35 Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikrein‐kininogen‐kinin system: lessons from the quantification of endogenous kinins. Peptides 2000 ; 21: 1903 ‐ 40.
36. 36 Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 1992 ; 56: 131 ‐ 90.
37. 37 Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998 ; 50: 357 ‐ 86.
38. 38 Erdos EG, Skidgel RA. Metabolism of bradykinin by peptidases in health and disease. In: Farmer SG, ed. Handbook of immunopharmacology: the Kinin system. London: Academic Press, 1997;111‐141.
39. 39 Decarie A, Raymond P, Gervais N, et al. Serum interspecies differences in metabolic pathways of bradykinin and (des‐Arg9)BK: influence of enalaprilat. Am J Physiol Heart Circ Physiol 1996 ; 270: H1340 ‐ 7.
40. 40 Cyr M, Lepage Y, Blais C Jr, et al. Bradykinin and des‐Arg(9)‐bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001 ; 281: H275 ‐ 83.
41. 41 Decarie A, Drapeau G, Closset J, et al. Development of digoxigenin‐labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 1994 ; 15: 511 ‐ 8.
42. 42 Raymond P, Drapeau G, Raut R, et al. Quantification of des‐Arg 9 ‐bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J Immunol Methods 1995 ; 180: 247 ‐ 57.
43. 43 Rice J. Mathematical statistics and data analysis. Belmont: Duxbury Press, 1995:602.
44. 44 Simmons WH, Orawski AT. Membrane‐bound aminopeptidase P from bovine lung. Its purification, properties, and degradation of bradykinin. J Biol Chem 1992 ; 267: 4897 ‐ 903.
45. 45 Skidgel RA. Human carboxypeptidase N: lysine carboxypeptidase. Methods Enzymol 1995 ; 248: 653 ‐ 63.
46. 46 Marinella MA. Angio‐oedema induced by ACE inhibitors. J Intern Med 1996 ; 239: 371 ‐ 2.
47. 47 Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin‐converting enzyme inhibitors. Immunopharmacology 1999 ; 44: 21 ‐ 5.
48. 48 Blais C Jr, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des‐Arg 9 ‐bradykinin in patients with angiotensin‐converting enzyme inhibitor‐associated angioedema. Immunopharmacology 1999 ; 43: 293 ‐ 302.
49. 49 Adam A, Cugno M, Molinaro G, et al. Patients with a history of ACE‐inhibitor induced angioedema have low plasma levels of aminopeptidase P. Lancet 2002 (in press).
50. 50 Sakamoto K, Sugimoto K, Fujimura A. Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes. Life Sciences 2000 ; 67: 2159 ‐ 65.
51. 51 Kim KS, Kumar S, Simmons WH, Brown NJ. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin‐converting enzyme inhibitor‐treated humans. J Pharmacol Exper Therap 2000 ; 292: 295 ‐ 8.
52. 52 Kitamura S, Carbini LA, Simmons WH, Scicli AG. Effects of aminopeptidase P inhibition on kinin‐mediated vasodepressor responses. Am J Physiol 1999 ; 276: H1664 ‐ 71.
53. 53 Keller C, Grutzmacher P, Bahr F, et al. LDL‐apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors (letter). Lancet 1993 ; 341: 60 ‐ 1.
54. 54 Sinzinger H, Bednar J, Granegger S, et al. LDL‐apheresis and concomitant ACE‐inhibitor therapy. Atherosclerosis 1994 ; 105: 115 ‐ 6.
55. 55 Yamamoto A, Kojima S, Shiba‐Harada M, et al. Assessment of the biocompatibility and long‐term effect of LDL‐apheresis by dextran sulfate‐cellulose column. Artif Organs 1992 ; 16: 177 ‐ 81.
56. 56 Davidson DC, Peart I, Turner S, Sangster M. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis. Lancet 1994 ; 343: 1575.